Treatment of Pediatric Very High-risk Acute Lymphoblastic Leukemia in Korea
Trial statusRecruiting
Trial phasePhase 2
Trial typeInterventional
Biological sexAll
Age1-19
SponsorHyoung Jin Kang
About this trial
Very high-risk acute lymphoblastic leukemia
Eligibility criteria
Qualifiers
Philadelphia chromosome-positive t(9;22)(q34;q11) or
Patients with failed remission who had blast > 5% on bone marrow test after initial remission induction therapy or
Hypodiploidy (Number of chromosomes < 44 (less than 44)) or
E2A-HLF(Hepatic Leukemia Factor) translocation-positive or
Disqualifiers
Participants with contraindications to medications
When the study participant or their legal representative withdraws consent
Pregnant or lactating women (patients of child-bearing potential require adequate contraception during the study period)
Participants who are medically unsuitable to participate in this study at the discretion of the investigator Participants participating in other interventional studies other than this protocol
Trial design
Treatments tested in this trial
- Dasatinib(Sprycel) arm
- Non-Dasatinib(Sprycel) arm
Treatment groups
74 Participants
are divided into 2 treatment groupsSponsors and collaborators
Hyoung Jin Kang
Lead sponsor
Seoul National University Hospital
Sponsor institution
Asan Medical Center
Collaborator
Samsung Medical Center
Collaborator
Severance Hospital
Collaborator
Pusan National University Yangsan Hospital
Collaborator
Seoul St. Mary's Hospital
Collaborator
Source ClinicalTrials.gov